We show that CLK inhibitor is more effective against MYC‐activated cancer, consistent with previous reports that MYC‐driven cancers are vulnerable to spliceosome inhibition (Hsu et al, 2015; Koh et al, 2015). The gene discussed is MYC; the disease is cancer.